Significant proportion of breast and/or ovarian cancer families of french Canadian descent harbor 1 of 5 BRCA1 and BRCA2 mutations

被引:42
作者
Oros, KK
Ghadirian, P
Greenwood, CMT
Perret, C
Shen, Z
Paredes, Y
Arcand, SL
Mes-Masson, AM
Narod, SA
Foulkes, WD
Provencher, D
Tonin, PN
机构
[1] McGill Univ, Dept Human Genet, Montreal, PQ, Canada
[2] Univ Montreal, Hop Hotel Dieu, CHU Montreal, Fac Med,Unite Rech Epidemiol, Montreal, PQ, Canada
[3] Hosp Sick Children, Program Genet & Genom Biol, Toronto, ON M5G 1X8, Canada
[4] CHU Montreal, Notre Dame Hosp, Inst Canc Montreal, Ctr Rech, Montreal, PQ, Canada
[5] McGill Univ, Ctr Hlth, Res Inst, Montreal, PQ H3A 2T5, Canada
[6] Univ Montreal, Ctr Res Womens Hlth, Montreal, PQ, Canada
[7] McGill Univ, Dept Oncol, Program Canc Genet, Montreal, PQ, Canada
[8] McGill Univ, Dept Med, Montreal, PQ, Canada
[9] Univ Montreal, Div Gynecol Oncol, Montreal, PQ, Canada
关键词
BRCA1; BRCA2; French Canadian; founder mutation;
D O I
10.1002/ijc.20406
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
In 1998, we reported that a significant proportion of breast and/or ovarian cancer families of French Canadian descent harbor specific germline mutations in BRCA1 or BRCA2 attributed to common founders. Here we report the frequency of previously described mutations (n = 7) and 13 mutations identified in French Canadian families since 1998, in a new group of families (n = 88). Four of the previously described mutations, 4446C > T, 2953delGTAinsC, 8765delAG and 6085C > T, account for 72% and 69% of mutation-positive families in previously (n = 81) and recently ascertained groups, respectively. Only 2 of 13 recently identified mutations were found in more than I family: 3875delGTCT (n = 2) and 3398delAAAAG (n = 4). The 2 groups (ascertained pre- and post-gene discovery) did not differ significantly when distribution of mutations based on cancer syndrome phenotype and age of diagnosis or number of breast cancer cases were compared. Five common mutations accounted for a significant proportion (84%) of all mutation-positive families. The age of diagnosis of female breast cancer in mutation-negative families was significantly higher than that of the mutation-positive families (p < 0.0001). The total number of cases of cancer per family was significantly lower in mutation-negative than mutation-positive families (p < 0.001). Our results define a new mutation panel for screening BRCA1/2 mutations and the phenotype of mutation-positive families harboring the common mutations in the French Canadian population. (C) 2004 Wiley-Liss. Inc.
引用
收藏
页码:411 / 419
页数:9
相关论文
共 45 条
[1]   A comprehensive model for familial breast cancer incorporating BRCA1, BRCA2 and other genes [J].
Antoniou, AC ;
Pharoah, PDP ;
McMullan, G ;
Day, NE ;
Stratton, MR ;
Peto, J ;
Ponder, BJ ;
Easton, DF .
BRITISH JOURNAL OF CANCER, 2002, 86 (01) :76-83
[2]  
BEAUPRE M, 2002, SURVEILLANCE CANC QU
[3]   MUTATIONS IN THE BRCA1 GENE IN FAMILIES WITH EARLY-ONSET BREAST AND OVARIAN-CANCER [J].
CASTILLA, LH ;
COUCH, FJ ;
ERDOS, MR ;
HOSKINS, KF ;
CALZONE, K ;
GARBER, JE ;
BOYD, J ;
LUBIN, MB ;
DESHANO, ML ;
BRODY, LC ;
COLLINS, FS ;
WEBER, BL .
NATURE GENETICS, 1994, 8 (04) :387-391
[4]   Prevalence of founder BRCA1 and BRCA2 mutations in unselected French Canadian women with breast cancer [J].
Chappuis, PO ;
Hamel, N ;
Paradis, AJ ;
Deschênes, J ;
Robidoux, A ;
Potvin, C ;
Cantin, J ;
Tonin, P ;
Ghadirian, P ;
Foulkes, WD .
CLINICAL GENETICS, 2001, 59 (06) :418-423
[5]  
CHARBONNEAU H, 1987, BEGINNING 1800, V1
[6]  
Claes K, 1999, Hum Mutat, V13, P256, DOI 10.1002/(SICI)1098-1004(1999)13:3<256::AID-HUMU12>3.0.CO
[7]  
2-M
[8]  
Claus EB, 1996, CANCER, V77, P2318, DOI 10.1002/(SICI)1097-0142(19960601)77:11<2318::AID-CNCR21>3.0.CO
[9]  
2-Z
[10]   After BRCA1 and BRCA2-what next? Multifactorial segregation analyses of three-generation, population-based Australian families affected by female breast cancer [J].
Cui, JS ;
Antoniou, AC ;
Dite, GS ;
Southey, MC ;
Venter, DJ ;
Easton, DF ;
Giles, GG ;
McCredie, MRE ;
Hopper, JL .
AMERICAN JOURNAL OF HUMAN GENETICS, 2001, 68 (02) :420-431